The anti-fasciolasis properties of silver nanoparticles produced by Trichoderma harzianum and their improvement of the anti-fasciolasis drug Triclabendazole

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 21887-21898

  Gherbawy, Youssuf A ^a,b   Shalaby, Ismail M ^a   El Sadek, Mahmoud Syed Abd ^c   Elhariry, Hesham M ^a,d   Abdelilah, Banaja A ^a  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b SOUTH VALLEY UNIVERSITY   (Egypt)

^c SOUTH VALLEY UNIVERSITY   (Egypt)

^d Ain Shams University   (Egypt)

Author keywords

Egg hatching; Fasciola; Silver nanoparticle; Trichoderma; Triclabendazole

Indexed keywords

SILVER NANOPARTICLE; SILVER NITRATE; TRICLABENDAZOLE;

ANTHELMINTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; CELL WALL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG SYNTHESIS; FASCIOLA HEPATICA; FASCIOLIASIS; FUNGAL METABOLISM; FUNGAL STRAIN; HYPOCREA LIXII; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ULTRAVIOLET SPECTROSCOPY;

BENZIMIDAZOLES; DRUG COMBINATIONS; FASCIOLIASIS; HUMANS; METAL NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; SILVER; TRICHODERMA;

EID: 84887194979     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141121887     Document Type: Article

References (55)

1. Haridy, F. M.; Morsy, T. A.; Gawish, N. I.; Antonios, T. N.; Abdel Gawad, A. G. The potential reservoir role of donkeys and horses in zoonotic fascioliasis in Gharbia Governorate. Egypt. J. Egypt. Soc. Parasitol. 2002, 32, 561-570.
2. Farag, H. F. Human fascioliasis in some countries of the Eastern Mediterranean Region. East. Mediterr. Health J. 1998, 4, 156-160.
3. Haseeb, A. N.; El-Shazly, A. M.; Arafa, M. A.; Morsy, A. T. A review on fascioliasis in Egypt. J. Egypt. Soc. Parasitol. 2002, 32, 317-354.
4. Lotfy, W. M.; El-Morshedy, H. N.; Abou El-Hoda, M.; El-Tawila, M. M.; Omarb, E. A.; Farag, H. F. Identification of the Egyptian species of Fasciola. Vet. Parasitol. 2002, 103, 323-332.
5. Mekroud, A.; Benakhla, A.; Vignoles, P.; Rondelaud, D.; Dreyfuss, G. Preliminary studies on the prevalences of natural fasciolosis in cattle, sheep, and the host snail (Galba truncatula) in north-eastern Algeria. Parasitol. Res. 2004, 92, 502-505.
6. Keyyu, J. D.; Kassuku, A. A.; Msalilwa, L. P.; Monrad, J.; Kyvsgaard, N. C. Cross-sectional prevalence of helminth infections in cattle on traditional, small-scale and large-scale dairy farms in Iringa district, Tanzania. Vet. Res. Commun. 2006, 30, 45-55.
7. Mungube, E. O.; Bauni, S. M.; Tenhagen, B. A.; Wamae, L. W.; Nginyi, J. M.; Mugambi, J. M. The prevalence and economic significance of Fasciola gigantica and Stilesia hepatica in slaughtered animals in the semi-arid coastal Kenya. Trop. Anim. Health Prod. 2006, 38, 475-483.
8. Pfukenyi, D. M.; Mukaratirwa, S.; Willingham, A. L.; Monrad, J. Epidemiological studies of Fasciola gigantica infections in cattle in the highveld and lowveld communal grazing areas of Zimbabwe. Onderstepoort J. Vet. Res. 2006, 73, 37-51.
9. Phiri, A. M.; Phiri, I. K.; Chota, A.; Monrad, J. Trematode infections in freshwater snails and cattle from the Kafue wetlands of Zambia during a period of highest cattle-water contact. J. Helminthol. 2007, 81, 85-92.
10. Ali, H.; Ai, L.; Song, H. Q.; Ali, S.; Lin, R. Q.; Seyni, B.; Issa, G.; Zhu, X. Q. Genetic characterisation of Fasciola samples from different host species and geographical localities revealed the existence of F. hepatica and F. gigantica in Niger. Parasitol. Res. 2008, 102, 1021-1024.
11. Hammami, H.; Hamed, N.; Ayadi, A. Epidemiological studies on Fasciola hepatica in Gafsa Oases (south west of Tunisia). Parasite 2007, 14, 261-264.
12. Banaja, A. A.; Ghandour, A. M. A review of parasites of camels in Saudi Arabia. J. KSU Sci. 1994, 6, 75-86.
13. Al-Megrin, W. Prevalence of intestinal parasites in leafy vegetables in Riyadh, Saudi Arabia. Int. J. Zool. Res. 2010, 6, 190-195.
14. Sanad, M. M.; Al-Megrin, W. A. Fascioliasis among local and imported sheep in Saudi Arabia: Parasitological and serological diagnosis. J. Egypt. Soc. Parasitol. 2005, 35, 1121-1134.
15. Eligail, A. M.; Masawi, A. M.; Al-Jaser, N. M.; Abdelrahman, K. A.; Shah, A. H. Audit of stool analysis results to ensure the prevalence of common types of intestinal parasites in Riyadh region, Saudi Arabia. Saudi J. Biol. Sci. 2010, 17, 1-4.
16. Abou-Zinadah, N. Y.; Fouad, M. A. Anti-Fasciola antibodies among rodents and sheep in Jeddah, Saudi Arabia. J. Egypt. Soc. Parasitol. 2005, 35, 711-716.
17. McManus, D. P.; Dalton, J. P. Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 2006, 133, S43-S61.
18. Keiser, J.; Morson, G. Fasciola hepatica: Tegumental alterations in adult flukes following in vitro and in vivo administration of artesunate and artemether. Exp. Parasitol. 2008, 118, 228-237.
19. Alvarez-Sanchez, M. A.; Mainar-Jaime, R. C.; Perez-Garcia, J.; RojoVazquez, F. A. Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain. Vet. Rec. 2006, 159, 424-425.
20. Keiser, J.; Engels, D.; Büscher, G.; Utzinger, J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin. Investig. Drugs 2005, 14, 1513-1526.
21. Curtis, A.; Wilkinson, C. Nantotechniques and approaches in biotechnology. Trends Biotechnol. 2001, 19, 97-101.
22. Oka, H.; Tomioka, T.; Tomita, K.; Nishino, A.; Ueda, S. Inactivation of enveloped viruses by a silver-thiosulfate complex. Met. Based Drugs 1994, 1, doi: 10. 1155/MBD. 1994. 511.
23. Angeli, E.; Buzio, R.; Firpo, G. Nanotechnology applications in medicine. Tumori 2008, 94, 206-215.
24. Debbage, P. Targeted drugs and nanomedicine: Present and future. Curr. Pharm. Des. 2009, 15, 153-172.
25. Elechiguerra, J. L.; Burt, J. L.; Morones, J. R.; Camacho-Bragado, A.; Gao, X.; Lara, H. H.; Yacaman, M. J. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol. 2005, 3, doi: 10. 1186/1477-3155-3-6.
26. Tokumaru, T.; Shimizu, Y.; Fox, C. L. Antiviral activities of silver sulfadiazine and ocular infection. Res. Commun. Chem. Pathol. Pharmacol. 1974, 8, 151-158.
27. Oloffs, A.; Grosse-Siestrup, C.; Bisson, S.; Rinck, M.; Rudolph, R.; Gross, U. Biocompatibility of silver-coated polyurethane catheters and silver-coated Dacron material. Biomaterials 1994, 15, 753-758.
28. Allahverdiyev, A. M.; Abamor, E. S.; Bagirova, M.; Ustundag, C. B.; Kaya, C.; Kaya, F.; Rafailovich, M. Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. Int. J. Nanomed. 2011, 6, 2705-2714.
29. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
30. Merisko-Liversidge, E.; Liversidge, G. G.; Cooper, E. R. Nanosizing: A formulation approach for poorly-watersoluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
31. Mansoori, G. A. Principles of Nanotechnology-Molecular-Based Study of Condensed Matter in Small Systems; World Scientific Pub. Co.: Hackensack, NJ, USA, 2005.
32. Fayaza, M.; Tiwaryb, C. S.; Kalaichelvana, P. T.; Venkatesanc, R. Blue orange light emission from biogenic synthesized silver nanoparticles using Trichoderma viride. Colloids Surf. B 2010, 75, 175-178.
33. El-Rafie, M. H.; Mohamed, A. A.; Shaheen, T. A.; Hebeish, A. Antimicrobial effect of silver nanoparticles produced by fungal process on cotton fabrics. Carbohydr. Polym. 2010, 80, 779-782.
34. Vahabi, K.; Mansoori, G. A.; Karimi, S. Biosynthesis of silver nanoparticles by fungus Trichoderma reesei (A route for large-scale production of AgNPs). Insci. J. 2011, 1, 65-79.
35. Devi, T. P.; Kulanthaivel, S.; Kamil, D.; Borah, J. L.; Prabhakaran, N.; Srinivasa, N. Biosynthesis of silver nanoparticles from Trichoderma species. Indian J. Exp. Biol. 2013, 51, 543-547.
36. Duran, N.; Marcato, P.; Alves, O.; de Souza, G.; Esposito, E. Mechanistic aspects of biosynthesis of silver nanoparticles by several Fusarium oxysporum strains. J. Nanobiotechnol. 2005, 3, 1-7.
37. Ottow, J. C. G.; von Klopotek, A. Enzymatic reduction of iron oxide by fungi. Appl. Microbiol. 1969, 18, 41-43.
38. Mulvaney, P. Surface plasmon spectroscopy of nanosized metal particles. Langmuir 1996, 12, 788-800.
39. Vigneshwaran, N.; Kathe, A. A.; Varadarajan, P. V.; Nachane, R. P.; Balasubramanya, R. H. Silver-protein (core-shell) nanoparticle production using spent mushroom substrate. Langmuir 2007, 23, 7113-7117.
40. Li, G.; He, D.; Qian, Y.; Guan, B.; Gao, S.; Cui, Y.; Yokoyama, K.; Wang, L. Fungus-mediated green synthesis of silver nanoparticles using Aspergillus terreus. Int. J. Mol. Sci. 2012, 13, 466-476.
41. Lu, Z.; Rong, K.; Li, J.; Yang, H.; Chen, R. Size-dependent antibacterial activities of silver nanoparticles against oral anaerobic pathogenic bacteria. J. Mater. Sci. Mater. Med. 2013, 24, 1465-1471.
42. Moll, L.; Gaasenbeek, C. P.; Vellema, P.; Borgsteede, F. H. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands. Vet. Parasitol. 2000, 91, 153-158.
43. Raadsma, H. W.; Kingsford, N. M.; Suharyanta, T. W.; Spithill, D. P. Host responses during experimental infection with Fasciola gigantic and Fasciola hepatica in Merino sheep I. Comparative immunological and plasma biochemical changes during early infection. Vet. Parasitol. 2007, 143, 275-286.
44. Ramírez, N.; Mayet, L.; del Rivero, L.; Ibarra-Velarde, F.; Castillo, R.; Hernández-Campos, A.; Jung-Cook, H. Pharmacokinetic behaviour in sheep and cattle of 5-Chloro-2-(methylthio)-6-(1-naphthyloxy)-1H-benzimidazole, a new fasciolicide agent. J. Vet. Pharmacol. Ther. 2009, 32, 154-159.
45. Lacey, E. Mode of action of benzimidazoles. Parasitol. Today 1990, 6, 112-115.
46. Fairweather, I. Triclabendazole: New skills to unravel an old(ish) enigma. J. Helminthol. 2005, 79, 227-234.
47. Fairweather, I. Triclabendazole progress report 2005-2009: An advancement of learning? J. Helminthol. 2009, 83, 139-150.
48. Alvarez, L.; Moreno, G.; Moreno, L.; Ceballos, L.; Shaw, L.; Fairweather, I.; Lanusse, C. Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs. Vet. Parasitol. 2009, 164, 211-216.
49. Ansari, M. A.; Khan, H. M.; Khan, A. A.; Ahmad, M. K.; Mahdi, A. A.; Pal, R.; Cameotra, S. S. Interaction of silver nanoparticles with Escherichia coli and their cell envelope biomolecules. J. Basic Microbiol. 2013, doi: 10. 1002/jobm. 201300457.
50. Fawaz, F.; Bonini, F.; Maugein, J.; Lagueny, A. M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: Pharmacokinetics and in vitro antimicrobial activity. Int. J. Pharm. 1998, 168, 255-259.
51. Fattal, E.; Rojas, J.; Youssef, M.; Couvreur, P.; Andremont, A. Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob. Agents Chemother. 1991, 35, 770-772.
52. Mohammadi, G.; Valizadeh, H.; Barzegar-Jalali, M.; Lotfipour, F.; Adibkia, K.; Milani, M.; Azhdarzadeh, M.; Kiafar, F.; Nokhodchi, A. Development of azithromycin-PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf. B Biointerfaces 2010, 80, 34-39.
53. Mas, N.; Galiana, I.; Mondragon, L.; Aznar, E.; Climent, E.; Cabedo, N.; Sancenón, F.; Murguía, J. R.; Martínez-Máñez, R.; Marcos, M. D.; Amorós, P. Enhanced efficacy and broadening of antibacterial action of drugs via the use of capped mesoporous nanoparticles. Chem. A Eur. J. 2013, 34, 11167-11171.
54. Chu, Z.; Yin, C.; Zhang, S.; Lin, G.; Li, Q. Surface plasmon enhanced drug efficacy using core-shell Au@SiO2 nanoparticle carrier. Nanoscale 2013, 5, 3406-3411.
55. Fairweather, I.; McShane, D. D.; Trudgett, A.; Brenna, G. P.; Shaw, L.; Ellison, S. E.; O'Hagan, N. T.; York, E. A.; Trudgett, A.; Brennan, G. P. Development of an egg hatch assay for the diagnosis of triclabendazole resistance in Fasciola hepatica: Proof of concept. Vet. Parasitol. 2012, 183, 249-259.